Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Gene study offers hope for treating fatal illness in children and dogs
Using SingleCut CRISPR gene editing, they managed to modify the dogs’ own DNA so they began producing dystrophin again.

Doctors and vets team up to study Duchenne muscular dystrophy

Vets and medics say they have made a significant breakthrough in the search for a treatment for Duchenne muscular dystrophy (DMD) - a fatal disease that affects children and dogs.

Scientists from the Royal Veterinary College and UT Southwestern Medical Centre used gene editing techniques in dogs, to restore the production of a protein that is absent in DMD patients.

DMD is the most common fatal genetic disease in children and it also occurs in many dog breeds. Patients with the disease produce almost no dystrophin, a protein that helps to protect muscle fibres and the heart when they contract. As a result, the patient’s muscles are damaged, leading to an inability to walk, skeletal deformities and heart failure.

The team said they may have come up with a single intravenous injection to treat the most common genetic mutations.

A naturally occurring mutation in the dystrophin gene was found in a dog that was being treated at the RVC’s Small Animal Referral Hospital, and the team are now working with the dog’s relatives. Using SingleCut CRISPR gene editing, they managed to modify the dogs’ own DNA so they began producing dystrophin again.

In a dog that received the highest dose, the cardiac muscles restored dystrophin protein to levels up to 92 per cent of the normal amount after treatment.

Scientists believe this is the first time this type of gene editing therapy has been used after birth in an animal larger than a rodent. It is hoped there will be a human application, after long-term research, efficacy and safety testing.

Richard Piercy, professor of comparative neuromuscular disease at the RVC, said: “There is more work to be done, but with this exciting breakthrough, we feel we are a significant step closer to finding an effective treatment.
 
“A great many genetic diseases affect humans, dogs and other species - many, like DMD - with tragic consequences and this form of gene editing treatment might well be applicable in many of them. We’re hopeful that we’re paving the way for future research into treating some of the most serious genetic conditions that affect us today.”

Preliminary findings have been published in the journal Science.

Image © RVC
 

Become a member or log in to add this story to your CPD history

RCVS Knowledge appoints Veterinary Evidence editor-in-chief

News Story 1
 RCVS Knowledge has welcomed Professor Peter Cockcroft as editor-in-chief for Veterinary Evidence.

A world-renowned expert in evidence-based veterinary medicine, Prof Cockcroft will lead the strategic development and editorial quality of the open-access journal. He was previously in the role from 2017-2020.

Katie Mantell, CEO of RCVS Knowledge, said: "We are excited about the extensive knowledge of evidence-based veterinary medicine and clinical veterinary research that Peter brings, and we look forward to working with him over this next phase of the journal's development." 

Click here for more...
News Shorts
Defra to host bluetongue webinar for vets

The Department for Environment, Food and Rural Affairs (Defra) will be hosting a webinar for veterinary professional on bluetongue on Thursday, 25 April 2024.

Topics covered will include the transmission cycle, pathology and pathogenesis, clinical signs (including signs seen in recent BTV-3 cases in the Netherlands), and control and prevention.

The session, which will take place from 6pm to 7.30pm, is part of Defra's 'Plan, Prevent and Protect' webinar series, which are hosted by policy officials, epidemiologists and veterinary professionals from Defra and the Animal and Plant Health Agency. The bluetongue session will also feature insights from experts from The Pirbright Institute.

Those attending will have the opportunity to ask questions. Places on the webinar can be booked online.